In this article, Michael J Bloch, MD, discusses the usage of RAS-blocking agents, slowing the progression of end-stage renal disease, and reducing cardiovascular events in patients with advanced kidney...
In this article, Michael J Bloch, MD, discusses the usage of RAS-blocking agents, slowing the progression of end-stage renal disease, and reducing cardiovascular events in patients with advanced kidney...
In this article, Michael J Bloch, MD, discusses the usage of RAS-blocking agents, slowing the progression of end-stage renal disease, and reducing cardiovascular events in patients with advanced kidney...
In this article, Michael J Bloch, MD, discusses the usage of RAS-blocking agents, slowing the progression of end-stage renal disease, and reducing cardiovascular events in patients with advanced kidney...
In this article, Michael Bloch, MD, and Evan Bloch discuss findings from the SELECT trial, including the use of the glucagon-like peptide 1 receptor agonist, semaglutide, to reduce the risk of major...
In this article, Michael Bloch, MD, and Evan Bloch discuss findings from the SELECT trial, including the use of the glucagon-like peptide 1 receptor agonist, semaglutide, to reduce the risk of major...
In this article, Michael Bloch, MD, and Evan Bloch discuss findings from the SELECT trial, including the use of the glucagon-like peptide 1 receptor agonist, semaglutide, to reduce the risk of major...
In this article, Michael Bloch, MD, and Evan Bloch discuss findings from the SELECT trial, including the use of the glucagon-like peptide 1 receptor agonist, semaglutide, to reduce the risk of major...
In this article, Michael Bloch, MD, and Evan Bloch discuss findings from the SELECT trial, including the use of the glucagon-like peptide 1 receptor agonist, semaglutide, to reduce the risk of major...
In this article, Michael Bloch, MD, and Evan Bloch discuss findings from the SELECT trial, including the use of the glucagon-like peptide 1 receptor agonist, semaglutide, to reduce the risk of major...
